WST
West Pharmaceutical Services, Inc. NYSE Listed Mar 17, 1980$323.59
After hrs
$334.50
+2.00%
Mkt Cap $23.5B
52w Low $210.08
91.1% of range
52w High $334.66
50d MA $303.72
200d MA $271.23
P/E (TTM)
47.6x
EV/EBITDA
31.8x
P/B
7.4x
Debt/Equity
0.1x
ROE
18.1%
P/FCF
50.2x
RSI (14)
54.30
ATR (14)
$7.33
Beta
1.15
50d MA
$303.72
200d MA
$271.23
Avg Volume
745.0K
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
530 Herman O. West Drive · Exton, PA 19341-0645 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 1.68 | 2.13 | +26.8% | 309.70 | +2.0% | -1.1% | -1.3% | -3.3% | +1.1% | +0.8% | — |
| Feb 12, 2026 | AMC | 1.83 | 2.04 | +11.5% | 243.61 | +0.1% | +2.8% | -2.9% | +2.1% | -1.8% | -1.1% | — |
| Oct 23, 2025 | AMC | 1.68 | 1.96 | +16.7% | 307.25 | +0.2% | -3.2% | -3.4% | -1.3% | +0.5% | -2.2% | — |
| Jul 24, 2025 | AMC | 1.51 | 1.84 | +21.9% | 279.10 | +0.0% | -5.6% | -2.2% | -1.9% | -1.5% | -4.0% | — |
| Apr 24, 2025 | AMC | 1.22 | 1.45 | +18.9% | 210.59 | +2.0% | +1.9% | +0.7% | -1.2% | -1.0% | -0.5% | — |
| Feb 13, 2025 | AMC | 1.71 | 1.82 | +6.4% | 199.11 | +1.8% | +7.8% | -1.7% | -4.0% | +0.6% | +3.6% | — |
| Oct 24, 2024 | AMC | 1.50 | 1.85 | +23.3% | 330.65 | -0.8% | -6.9% | +0.8% | +2.6% | -1.7% | -1.6% | — |
| Jul 25, 2024 | AMC | 1.74 | 1.52 | -12.6% | 277.16 | +0.9% | +2.7% | +1.2% | +4.0% | +2.2% | -1.3% | — |
| Apr 25, 2024 | AMC | 1.26 | 1.56 | +23.8% | 368.18 | -1.1% | -2.1% | -1.7% | +0.9% | +1.7% | +1.4% | — |
| Feb 15, 2024 | AMC | 1.78 | 1.83 | +2.8% | 350.70 | +0.0% | +3.2% | -3.3% | +1.7% | +1.0% | +2.1% | — |
| Oct 26, 2023 | AMC | 1.86 | 2.16 | +16.1% | 327.32 | -0.5% | -2.0% | -0.3% | -0.5% | +1.1% | +1.9% | — |
| Jul 27, 2023 | AMC | 1.93 | 2.11 | +9.3% | 354.90 | +1.1% | +3.0% | +0.7% | +1.0% | -0.3% | -0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 9 | Barclays | Upgrade | Equal Weight → Overweight | $400 | $319.75 | $327.45 | +2.4% | +4.7% | -1.1% | -0.2% | -0.5% | +0.8% |
| Jun 2 | Wolfe Research | Reiterates | Outperform | $375 | $316.30 | $314.18 | -0.7% | -1.3% | +1.3% | +0.3% | -0.9% | +1.7% |
| Apr 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $306.16 | $304.40 | -0.6% | -1.3% | -3.3% | +1.1% | +0.8% | +1.0% |
| Apr 14 | Barclays | Maintains | Equal Weight → Equal Weight | — | $259.96 | $261.18 | +0.5% | +3.1% | -0.5% | +1.2% | +1.5% | +1.6% |
| Feb 13 | Barclays | Maintains | Equal Weight → Equal Weight | — | $243.61 | $243.94 | +0.1% | +2.8% | -2.9% | +2.1% | -1.8% | -1.1% |
| Feb 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $237.50 | $233.84 | -1.5% | -2.8% | +2.6% | -2.3% | +7.5% | -0.0% |
| Oct 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $297.47 | $299.99 | +0.8% | -3.4% | -1.3% | +0.5% | -2.2% | +1.3% |
| Oct 24 | UBS | Maintains | Buy → Buy | — | $307.25 | $307.94 | +0.2% | -3.2% | -3.4% | -1.3% | +0.5% | -2.2% |
| Oct 24 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $307.25 | $307.94 | +0.2% | -3.2% | -3.4% | -1.3% | +0.5% | -2.2% |
| Oct 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $277.00 | $301.06 | +8.7% | +10.9% | -3.2% | -3.4% | -1.3% | +0.5% |
| Oct 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $271.42 | $269.52 | -0.7% | +0.6% | -0.2% | -1.6% | -0.8% | +0.7% |
| Jul 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $279.10 | $279.10 | +0.0% | -5.6% | -2.2% | -1.9% | -1.5% | -4.0% |
| Jul 25 | UBS | Maintains | Buy → Buy | — | $279.10 | $279.10 | +0.0% | -5.6% | -2.2% | -1.9% | -1.5% | -4.0% |
| Jul 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $279.10 | $279.10 | +0.0% | -5.6% | -2.2% | -1.9% | -1.5% | -4.0% |
| Feb 14 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $199.11 | $202.67 | +1.8% | +7.8% | -1.7% | -4.0% | +0.6% | +3.6% |
| Dec 13 | BofA Securities | Maintains | Buy → Buy | — | $331.62 | $329.68 | -0.6% | -0.5% | +0.2% | +1.1% | -2.7% | +0.5% |
| Dec 12 | UBS | Upgrade | Neutral → Buy | — | $318.22 | $320.90 | +0.8% | +4.2% | -0.5% | +0.2% | +1.1% | -2.7% |
| Feb 16 | UBS | Maintains | Neutral → Neutral | — | $350.70 | $350.82 | +0.0% | +3.2% | -3.3% | +1.7% | +1.0% | +2.1% |
| Feb 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $406.63 | $402.43 | -1.0% | -2.0% | +2.4% | -14.1% | +3.2% | -3.3% |
| Feb 7 | Jefferies | Upgrade | Hold → Buy | — | $398.27 | $408.08 | +2.5% | +3.7% | -0.5% | -0.3% | -0.7% | -2.0% |
| Oct 27 | Stephens & Co. | Maintains | Overweight → Overweight | — | $327.32 | $325.73 | -0.5% | -2.0% | -0.3% | -0.5% | +1.1% | +1.9% |
| Aug 30 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $412.41 | $414.65 | +0.5% | -0.8% | -0.5% | +0.2% | -1.0% | +0.3% |
| Aug 21 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $387.77 | $389.90 | +0.5% | +1.3% | +0.1% | -0.0% | -0.3% | +0.5% |
| Jul 28 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $354.90 | $358.85 | +1.1% | +3.0% | +0.7% | +1.0% | -0.3% | -0.2% |
| Jul 17 | Stephens & Co. | Maintains | Overweight → Overweight | — | $385.13 | $385.19 | +0.0% | -0.4% | +0.3% | +0.3% | -1.8% | -0.4% |
| Jun 16 | BofA Securities | Upgrade | Neutral → Buy | — | $359.80 | $366.83 | +2.0% | +0.6% | +1.1% | +0.8% | -0.1% | -0.5% |
| Apr 11 | Stephens & Co. | Upgrade | Equal Weight → Overweight | — | $349.79 | $355.06 | +1.5% | +1.4% | +1.1% | +2.2% | -0.8% | -0.4% |
| Feb 17 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $319.77 | $317.18 | -0.8% | -1.9% | -2.2% | -0.4% | +2.1% | -0.6% |
| Dec 14 | Deutsche Bank | Maintains | Hold → Hold | — | $251.90 | $248.00 | -1.5% | -3.3% | -2.7% | -4.6% | +0.9% | -0.2% |
| Dec 2 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $242.02 | $235.58 | -2.7% | +1.0% | -2.0% | -1.9% | +0.4% | +0.1% |
| Nov 30 | UBS | Maintains | Neutral → Neutral | — | $223.50 | $224.11 | +0.3% | +5.0% | +3.1% | +1.0% | -2.0% | -1.9% |
| Oct 28 | BofA Securities | Downgrade | Buy → Neutral | — | $221.23 | $218.30 | -1.3% | +1.9% | +2.0% | -0.3% | -4.3% | -4.6% |
| Oct 28 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $221.23 | $218.30 | -1.3% | +1.9% | +2.0% | -0.3% | -4.3% | -4.6% |
| Jul 29 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $339.92 | $338.85 | -0.3% | +1.1% | -1.3% | +0.0% | +1.3% | -0.9% |
| Apr 29 | BofA Securities | Maintains | Buy → Buy | — | $325.36 | $323.07 | -0.7% | -3.2% | -0.9% | -1.9% | +3.9% | -1.2% |
| Apr 29 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $325.36 | $323.07 | -0.7% | -3.2% | -0.9% | -1.9% | +3.9% | -1.2% |
| Sep 15 | BofA Securities | Maintains | Buy → Buy | — | $452.06 | $453.73 | +0.4% | +0.1% | +0.4% | -1.3% | -0.9% | +0.8% |
| Jul 30 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $404.92 | $406.72 | +0.4% | +1.7% | +0.9% | +1.7% | +1.4% | -0.6% |
| Jul 30 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $404.92 | $406.72 | +0.4% | +1.7% | +0.9% | +1.7% | +1.4% | -0.6% |
| Apr 30 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $324.55 | $324.84 | +0.1% | +1.2% | +0.4% | -0.2% | -0.2% | +0.2% |
| Feb 19 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $296.74 | $297.68 | +0.3% | -5.1% | -3.2% | +0.6% | +1.7% | -0.4% |
| Nov 10 | KeyBanc | Maintains | Overweight → Overweight | — | $286.54 | $286.14 | -0.1% | -2.5% | +2.0% | +1.6% | +0.5% | +0.4% |
| Nov 10 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $286.54 | $286.14 | -0.1% | -2.5% | +2.0% | +1.6% | +0.5% | +0.4% |
| Oct 14 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $299.48 | $299.03 | -0.2% | -3.8% | +1.1% | +0.2% | -2.1% | +0.3% |
| Apr 24 | BofA Securities | Upgrade | Underperform → Neutral | — | $187.42 | $190.00 | +1.4% | +4.3% | +1.2% | -2.4% | -1.8% | -0.2% |
| Dec 12 | BofA Securities | Downgrade | Neutral → Underperform | — | $146.67 | $143.39 | -2.2% | -0.2% | -0.0% | +0.6% | +0.8% | +0.6% |
| Jul 26 | BofA Securities | Upgrade | Underperform → Neutral | — | $132.86 | $134.30 | +1.1% | +3.0% | +1.1% | -0.6% | -0.2% | +0.0% |
| May 1 | Jefferies | Downgrade | Buy → Hold | — | $123.79 | $121.45 | -1.9% | -2.6% | +1.0% | +0.8% | -0.1% | -1.1% |
| Apr 23 | William Blair | Maintains | Outperform → Outperform | — | $112.16 | $113.42 | +1.1% | +2.7% | +0.0% | +6.1% | +1.2% | -1.1% |
| Apr 25 | BofA Securities | Downgrade | Neutral → Underperform | — | $92.00 | $89.00 | -3.3% | -4.3% | +2.4% | -1.3% | -0.8% | -0.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Winters ChadOff | VP, Chief Accounting Officer | Sell | 896 | $300.67 | $269K | 1,522 | +0.76% | +0.83% |
| Apr 27, 2026 | Favorite Annette FOff | Sr. VP & Chief HR Officer | Sell | 2,817 | $305.20 | $860K | 16,828 | +0.76% | +0.83% |
8-K · 7.01
! Medium
West Pharmaceutical Services, Inc. -- 8-K 7.01: Regulation FD Disclosure
West Pharmaceutical Services disclosed material information via Form 8-K on April 23, 2026, though the specific disclosure details are not provided in this filing excerpt.
Apr 23
8-K · 5.02
!!! Very High
West Pharmaceutical Services, Inc. -- 8-K 5.02: Executive Change
West Pharmaceutical Services' CEO and board chair announced plans to retire once a successor is identified, signaling a leadership transition that investors should monitor for potential operational continuity impacts.
Mar 9
8-K · 7.01
! Medium
West Pharmaceutical Services, Inc. -- 8-K 7.01: Regulation FD Disclosure
West Pharmaceutical Services disclosed CFO personnel information in a Regulation FD filing, which typically indicates routine executive updates rather than material business developments affecting investor returns.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 4,683,286 | $1.2B | New | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 4,094,009 | $1.0B | New | Mar 2026 |
| 3 | Morgan Stanley | 3,063,716 | $843M | Added | Dec 2025 |
| 4 | Artisan Partners Limited Partnership | 2,657,893 | $666M | Reduced | Mar 2026 |
| 5 | Bank Of New York Mellon Corp | 2,465,858 | $618M | Reduced | Mar 2026 |
| 6 | Generation Investment Management Llp | 2,243,976 | $562M | Added | Mar 2026 |
| 7 | Longview Partners (Guernsey) Ltd | 1,315,403 | $330M | Added | Mar 2026 |
| 8 | Fmr Llc | 1,249,748 | $313M | Added | Mar 2026 |
| 9 | Apg Asset Management N.v. | 1,267,282 | $276M | Added | Mar 2026 |
| 10 | Invesco Ltd. | 1,056,007 | $265M | Added | Mar 2026 |
| 11 | Jpmorgan Chase & Co | 1,043,417 | $256M | Added | Mar 2026 |
| 12 | Liontrust Investment Partners Llp | 703,183 | $185M | Reduced | Mar 2026 |
| 13 | Northern Trust Corp | 731,283 | $183M | Added | Mar 2026 |
| 14 | Proshare Advisors Llc | 660,084 | $165M | Added | Mar 2026 |
| 15 | Amundi | 644,065 | $161M | New | Mar 2026 |
| 16 | Capital Research Global Investors | 604,011 | $151M | New | Mar 2026 |
| 17 | Sei Investments Co | 529,261 | $133M | Reduced | Mar 2026 |
| 18 | Arrowstreet Capital, Limited Partnership | 510,516 | $128M | Added | Mar 2026 |
| 19 | Viking Global Investors | 416,948 | $105M | Added | Mar 2026 |
| 20 | Nuveen, Llc | 408,990 | $103M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$23.52B
Enterprise Value
$23.03B
P/E (TTM)
47.59x
Forward P/E
37.74x
PEG Ratio
34.00x
P/B
7.37x
P/S
7.65x
P/FCF
50.17x
EV/EBITDA
31.83x
Shares Out
72.7M
Financials (TTM)
Revenue
$3.07B
Net Income
$493.7M
EBITDA
$723.6M
Free Cash Flow
$468.9M
Op Cash Flow
$754.8M
EPS Basic
$6.83
EPS Diluted
$6.80
EPS Forward
$8.57
Gross Margin
35.9%
Op Margin
20.1%
Net Margin
16.1%
Balance Sheet
Total Assets
$4.27B
Total Liab.
$1.09B
Total Equity
$3.18B
Cash
$791.3M
LT Debt
$298.4M
Book Value/Sh
$43.93
Debt/Equity
0.13x
Current Ratio
3.02
Quick Ratio
2.34
Returns & Growth
ROE
18.1%
ROA
13.2%
ROIC
13.6%
Rev Growth YoY
+6.3%
EPS Growth YoY
+1.2%
Price Returns
2W
+7.5%
1M
+8.5%
3M
+26.9%
6M
+16.4%
12M
+53.1%
Technicals
52W High
$334.66
52W Low
$210.08
50d MA
$303.72
200d MA
$271.23
RSI (14)
54.30
ATR (14)
$7.33
Beta
1.15
Avg Volume
745K
Dividends
Div Rate
$0.85
Div Yield
0.3%
Frequency
4
Ex-Div Date
Apr 29, 2026
Analyst Price Targets
Consensus
$315.83
High
$340.00
Low
$295.00
Median
$315.00
Data updated apr 27, 2026 10:02am
· Source: financialmodelingprep.com